Bone marrow microenvironment: The guardian of leukemia stem cells

被引:33
作者
Houshmand, Mohammad [1 ]
Blanco, Teresa Mortera [2 ]
Circosta, Paola [1 ]
Yazdi, Narjes [3 ]
Kazemi, Alireza [4 ]
Saglio, Giuseppe [1 ]
Zarif, Mahin Nikougoftar [2 ,5 ]
机构
[1] Univ Turin, Dept Clin & Biol Sci, I-10126 Turin, Italy
[2] Karolinska Inst, Ctr Hematol & Regenerat Med, Karolinska Univ Hosp Huddinge, Dept Med, S-14183 Stockholm, Sweden
[3] Islamic Azad Univ, Dept Mol Genet, Tehran Med Branch, Tehran 1916893813, Iran
[4] Shahid Beheshti Univ Med Sci, Sch Allied Med Sci, Dept Hematol & Blood Banking, Tehran 1985717443, Iran
[5] High Inst Res & Educ Intransfus Med, Blood Transfus Res Ctr, Tehran 146651157, Iran
来源
WORLD JOURNAL OF STEM CELLS | 2019年 / 11卷 / 08期
关键词
Bone marrow microenvironment; Bone marrow niche; Leukemic stem cell; Chronic myeloid leukemia; Acute myeloid leukemia; Target therapy; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; MINIMAL RESIDUAL DISEASE; BCR-ABL; ENDOTHELIAL-CELLS; PROGENITOR CELLS; TYROSINE KINASE; BETA-CATENIN; CML STEM; PROGNOSTIC-FACTOR;
D O I
10.4252/wjsc.v11.i8.476
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Bone marrow microenvironment (BMM) is the main sanctuary of leukemic stem cells (LSCs) and protects these cells against conventional therapies. However, it may open up an opportunity to target LSCs by breaking the close connection between LSCs and the BMM. The elimination of LSCs is of high importance, since they follow cancer stem cell theory as a part of this population. Based on cancer stem cell theory, a cell with stem cell-like features stands at the apex of the hierarchy and produces a heterogeneous population and governs the disease. Secretion of cytokines, chemokines, and extracellular vesicles, whether through autocrine or paracrine mechanisms by activation of downstream signaling pathways in LSCs, favors their persistence and makes the BMM less hospitable for normal stem cells. While all details about the interactions of the BMM and LSCs remain to be elucidated, some clinical trials have been designed to limit these reciprocal interactions to cure leukemia more effectively. In this review, we focus on chronic myeloid leukemia and acute myeloid leukemia LSCs and their milieu in the bone marrow, how to segregate them from the normal compartment, and finally the possible ways to eliminate these cells.
引用
收藏
页码:476 / 490
页数:15
相关论文
共 103 条
  • [31] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman, JM
    Melo, JV
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) : 1084 - 1086
  • [32] Immature CML cells implement a BMP autocrine loop to escape TKI treatment
    Grockowiak, Elodie
    Laperrousaz, Bastien
    Jeanpierre, Sandrine
    Voeltzel, Thibault
    Guyot, Boris
    Gobert, Stephanie
    Nicolini, Franck E.
    Maguer-Satta, Veronique
    [J]. BLOOD, 2017, 130 (26) : 2860 - 2871
  • [33] How I treat CML blast crisis
    Hehlmann, Ruediger
    [J]. BLOOD, 2012, 120 (04) : 737 - 747
  • [34] Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
    Herrmann, Harald
    Sadovnik, Irina
    Cerny-Reiterer, Sabine
    Ruelicke, Thomas
    Stefanzl, Gabriele
    Willmann, Michael
    Hoermann, Gregor
    Bilban, Martin
    Blatt, Katharina
    Herndlhofer, Susanne
    Mayerhofer, Matthias
    Streubel, Berthold
    Sperr, Wolfgang R.
    Holyoake, Tessa L.
    Mannhalter, Christine
    Valent, Peter
    [J]. BLOOD, 2014, 123 (25) : 3951 - 3962
  • [35] CD34+/CD38- stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin
    Herrmann, Harald
    Cerny-Reiterer, Sabine
    Gleixner, Karoline V.
    Blatt, Katharina
    Herndlhofer, Susanne
    Rabitsch, Werner
    Jaeger, Eva
    Mitterbauer-Hohendanner, Gerlinde
    Streubel, Berthold
    Selzer, Edgar
    Schwarzinger, Ilse
    Sperr, Wolfgang R.
    Valent, Peter
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (02): : 219 - 226
  • [36] Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches
    Hira, Vashendriya V. V.
    Van Noorden, Cornelis J. F.
    Carraway, Hetty E.
    Maciejewskic, Jaroslaw P.
    Molenaar, Remco J.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2017, 1868 (01): : 183 - 198
  • [37] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    Hochhaus, Andreas
    Larson, Richard A.
    Guilhot, Francois
    Radich, Jerald P.
    Branford, Susan
    Hughes, Timothy P.
    Baccarani, Michele
    Deininger, Michael W.
    Cervantes, Francisco
    Fujihara, Satoko
    Ortmann, Christine-Elke
    Menssen, Hans D.
    Kantarjian, Hagop
    O'Brien, Stephen G.
    Druker, Brian J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10) : 917 - 927
  • [38] CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
    Hosen, Naoki
    Park, Christopher Y.
    Tatsumi, Naoya
    Oji, Yusuke
    Sugiyama, Haruo
    Gramatzki, Martin
    Krensky, Alan M.
    Weissman, Irving L.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) : 11008 - 11013
  • [39] Chronic myeloid leukemia stem cells
    Houshmand, Mohammad
    Simonetti, Giorgia
    Circosta, Paola
    Gaidano, Valentina
    Cignetti, Alessandro
    Martinelli, Giovanni
    Saglio, Giuseppe
    Gale, Robert Peter
    [J]. LEUKEMIA, 2019, 33 (07) : 1543 - 1556
  • [40] Houshmand M, 2017, TISSUE ENG PART C-ME, V23, P72, DOI [10.1089/ten.TEC.2016.0404, 10.1089/ten.tec.2016.0404]